LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

Home・Elenco Azioni・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

81.69 0.88

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

81.33

Massimo

82.72

Metriche Chiave
By Trading Economics
Entrata	5.4M -48M
Vendite	6M 57M
Margine di Profitto	-82.974
Dipendenti	414
EBITDA	5.1M -43M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+59.18% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-565M 5.9B
Apertura precedente	80.81
Chiusura precedente	81.69

Notizie sul Sentiment di mercato

By Acuity

62%

38%

301 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

60 / 65.58 Supporto e resistenza

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2026, 23:43 UTC

Principali Notizie su Eventi

New Zealand's Unemployment Rate Falls in 1Q

5 mag 2026, 23:20 UTC

Azioni calde

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mag 2026, 21:48 UTC

Utili

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mag 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mag 2026, 00:00 UTC

Discorsi di Mercato

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mag 2026, 22:26 UTC

Discorsi di Mercato

AMD Data-Center Business Continues to Surge -- Market Talk

5 mag 2026, 22:20 UTC

Discorsi di Mercato

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mag 2026, 22:08 UTC

Utili

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mag 2026, 22:07 UTC

Utili

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Rev $1.2B >PAAS

5 mag 2026, 21:42 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:38 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:30 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:29 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:26 UTC

Utili

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mag 2026, 21:24 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:18 UTC

Utili

Mistras Backs 2026 Rev $730M-$750M >MG

5 mag 2026, 21:17 UTC

Utili

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mag 2026, 21:15 UTC

Utili

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mag 2026, 21:12 UTC

Utili

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mag 2026, 21:11 UTC

Utili

SSR Mining 1Q Rev $581.8M >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q EPS $1.16 >SSRM

5 mag 2026, 21:08 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:01 UTC

Utili

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mag 2026, 21:01 UTC

Azioni calde

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

59.18% in crescita

Previsioni per 12 mesi

Media 136.23 USD 59.18%

Alto 158 USD

Basso 105 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

60 / 65.58Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

301 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.